These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23188075)

  • 21. Cyclosporine for induction of remission in Crohn's disease.
    McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.
    Cohen SA; Aloi M; Arumugam R; Baker R; Bax K; Kierkuś J; Koletzko S; Lionetti P; Persson T; Eklund S
    Curr Med Res Opin; 2017 Jul; 33(7):1261-1268. PubMed ID: 28420280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Wang Y; Tsoulis DJ; MacDonald JK; Feagan BG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD003459. PubMed ID: 25099640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naltrexone therapy for Crohn's disease and ulcerative colitis.
    Weinstock LB
    J Clin Gastroenterol; 2014 Sep; 48(8):742. PubMed ID: 24583747
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
    Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
    J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.
    Israeli E; Zigmond E; Lalazar G; Klein A; Hemed N; Goldin E; Ilan Y
    World J Gastroenterol; 2015 May; 21(18):5685-94. PubMed ID: 25987796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budesonide for induction of remission in Crohn's disease.
    Rezaie A; Kuenzig ME; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH; Kaplan GG; Seow CH
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD000296. PubMed ID: 26039678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of a serious autistic disorder in a child with Naltrexone in an oral suspension form].
    Desjardins S; Doyen C; Contejean Y; Kaye K; Paubel P
    Encephale; 2009 Apr; 35(2):168-72. PubMed ID: 19393386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W;
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sargramostim for active Crohn's disease.
    Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
    N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study.
    Verburgt CM; Dunn KA; Otley A; Heyman MB; Verstraete S; Sunseri W; Sylvester F; de Meij T; Comeau A; Langille M; de Jonge WJ; Benninga MA; Van Limbergen JE
    BMJ Open; 2023 Feb; 13(2):e064944. PubMed ID: 36725090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
    Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children.
    Mahdi G; Israel DM; Hassall E
    Am J Gastroenterol; 1996 Jul; 91(7):1355-9. PubMed ID: 8677994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study.
    Hamann S; Sloan P
    J Opioid Manag; 2007; 3(3):137-44. PubMed ID: 18027539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.